Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV-infection: A prospective case-control study

被引:104
作者
Cauda, R
Tacconelli, E
Tumbarello, M
Morace, G
De Bernardis, F
Torosantucci, A
Cassone, A
机构
[1] Univ Cattolica Sacro Cuore, Ist Clin Malattie Infett, Dept Infect Dis, I-00168 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Dept Microbiol, Rome, Italy
[3] Ist Super Sanita, Dept Bacteriol & Med Micol, I-00161 Rome, Italy
来源
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 1999年 / 21卷 / 01期
关键词
HIV protease inhibitors; HAART; candidosis; Candida; HIV; AIDS;
D O I
10.1097/00126334-199905010-00003
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This study was conducted to evaluate the efficacy of highly active antiretroviral therapy (HAART) in preventing recurrence of oral candidosis (OC) associated with HIV. A prospective case-controlled observational study was performed in an inner-city university-hospital HIV/AIDS clinic. Ninety-three HIV-positive study subjects with a history of recurrent OC were divided into two groups: protease inhibitors (PI)-treated patients (group 1, n = 30) and non-PI-treated patients (group 2, n = 63). Study subjects were matched for sex, age, stage of HIV infection, and peripheral CD4(+) T-cell counts. The non-PI-treated group was further subdivided into the following three subgroups: HIV-positive study subjects treated with reverse transcriptase inhibitors (RTI; groups 2a and 2c) and HIV-positive study subjects not treated with RTIs (group 2b). Group 2c met the same inclusion criteria as group 2a had but was matched 6 months after the beginning of the study. We also assessed in vitro peripheral blood mononuclear cells (PBMC) and their lymphoproliferative response, as well as cutaneous delayed-type hypersensitivity (DTH) response to Candida-associated antigens in a randomly selected sample of study subjects divided into those treated with PIs and those who were not. During a 1-year follow-up, OC was diagnosed in 2 (7%) PI-treated and 23 (36%) non-PI-treated patients (p <.001). In addition to comparing findings in group 1 with those in group 2c, OC was detected in 14 (50%) non-PI-treated patients compared with no HAART-treated study subjects (p <.001). Only 41% of PI-treated study subjects had positive lymphoproliferative response in PBMCs and none was positive in terms of DTH to Candida antigens (p = not significant versus non-PI-treated study subjects). While objectively demonstrating a beneficial effect of HAART in preventing recurrence of OC infections, our findings suggest this effect cannot be not fully accounted for by reconstitution of anti-Candida cell-mediated immunity, given that other mechanisms, even of a nonimmune nature, could have some effect.
引用
收藏
页码:20 / 25
页数:6
相关论文
共 17 条
  • [1] Positive effects of combined antiretroviral therapy on CD4(+) T cell homeostasis and function in advanced HIV disease
    Autran, B
    Carcelain, G
    Li, TS
    Blanc, C
    Mathez, D
    Tubiana, R
    Katlama, C
    Debre, P
    Leibowitch, J
    [J]. SCIENCE, 1997, 277 (5322) : 112 - 116
  • [2] Long-term evaluation of cellular immunity during antiretroviral therapy and immunization with human immunodeficiency virus type 1 (HIV-1) Env glycoprotein in HIV-1-infected persons
    Carlesimo, M
    Pontesilli, O
    Guerra, EC
    Varani, AR
    Bernardi, ML
    Ricci, G
    Alario, C
    Pirillo, MF
    Mattiacci, G
    Leone, P
    Cassone, A
    Aiuti, F
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (04) : 904 - 912
  • [3] Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy
    Carr, A
    Marriott, D
    Field, A
    Vasak, E
    Cooper, DA
    [J]. LANCET, 1998, 351 (9098) : 256 - 261
  • [4] CASSONE A, 1998, 12 INT C AIDS GEN JU
  • [5] [Anonymous], 1992, MMWR Recomm Rep, V41, P1
  • [6] Evidence that members of the secretory aspartyl proteinase gene family, in particular SAP2, are virulence factors for Candida vaginitis
    De Bernardis, F
    Arancia, S
    Morelli, L
    Hube, B
    Sanglard, D
    Schäfer, W
    Cassone, A
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (01) : 201 - 208
  • [7] HIV-1 protease inhibitors - A review for clinicians
    Deeks, SG
    Smith, M
    Holodniy, M
    Kahn, JO
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (02): : 145 - 153
  • [8] Purification and biochemical characterization of a 65-kilodalton mannoprotein (MP65), a main target of Anti-Candida cell-mediated immune responses in humans
    Gomez, MJ
    Torosantucci, A
    Arancia, S
    Maras, B
    Parisi, L
    Cassone, A
    [J]. INFECTION AND IMMUNITY, 1996, 64 (07) : 2577 - 2584
  • [9] Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir
    Kelleher, AD
    Carr, A
    Zaunders, J
    Cooper, DA
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (02) : 321 - 329
  • [10] ORAL CANDIDIASIS IN HIGH-RISK PATIENTS AS THE INITIAL MANIFESTATION OF THE ACQUIRED IMMUNODEFICIENCY SYNDROME
    KLEIN, RS
    HARRIS, CA
    SMALL, CB
    MOLL, B
    LESSER, M
    FRIEDLAND, GH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (06) : 354 - 358